20 articles
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
Major study shows lifestyle intervention effectively reverses prediabetes in both African American and Caucasian participants with family diabetes history.
A sponsored 90-day trial of enhanced-absorption quercetin targeting cholesterol, blood sugar, and metabolic age was terminated before completion.
176-person study explored personalized responses to refined carbs, whole grains, and intermittent fasting for optimal glucose control.
A completed OSU trial investigates whether short-term exercise training can restore impaired mitochondrial cleanup pathways in overweight and obese skeletal muscle.
411-person study shows digital insulin delivery system helps optimize glucose control through automated dose tracking and mobile integration.
A Phase 1 trial tests whether lowering compensatory hyperinsulinemia with diazoxide improves glucose and lipid metabolism in NAFLD patients.
A completed Danish trial investigates how blocking IL-6 signaling with tocilizumab alters fat, glucose, and protein metabolism in humans.
German researchers test whether natural foods plus digital coaching can match diabetes remission rates of formula diets.
Small study tests whether combining Mediterranean eating, intermittent fasting, and exercise can reverse diabetes in 6 months.
Duke study shows high-quality egg protein combined with calorie restriction improves metabolic outcomes in older adults with prediabetes.
New study reveals how endurance exercise transforms fat-burning brown adipose tissue in just six weeks of training.
